Abstract
As an important aspect of computer-aided drug design, structure-based drug design brought a new horizon to pharmaceutical development. This in silico method permeates all aspects of drug discovery today, including lead identification, lead optimization, ADMET prediction and drug repurposing. Structure-based drug design has resulted in fruitful successes drug discovery targeting proteinligand and protein-protein interactions. Meanwhile, challenges, noted by low accuracy and combinatoric issues, may also cause failures. In this review, state-of-the-art techniques for protein modeling (e.g. structure prediction, modeling protein flexibility, etc.), hit identification/ optimization (e.g. molecular docking, focused library design, fragment-based design, molecular dynamic, etc.), and polypharmacology design will be discussed. We will explore how structure-based techniques can facilitate the drug discovery process and interplay with other experimental approaches.
Keywords: Structure-based drug design, protein modeling, focused library design, pharmacophore, flexible docking, high-throughput virtual screening, de novo design, protein-protein interaction, polypharmacology
Current Pharmaceutical Design
Title: From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Volume: 18 Issue: 9
Author(s): Lu Chen, John K. Morrow, Hoang T. Tran, Sharangdhar S. Phatak, Lei Du-Cuny and Shuxing Zhang
Affiliation:
Keywords: Structure-based drug design, protein modeling, focused library design, pharmacophore, flexible docking, high-throughput virtual screening, de novo design, protein-protein interaction, polypharmacology
Abstract: As an important aspect of computer-aided drug design, structure-based drug design brought a new horizon to pharmaceutical development. This in silico method permeates all aspects of drug discovery today, including lead identification, lead optimization, ADMET prediction and drug repurposing. Structure-based drug design has resulted in fruitful successes drug discovery targeting proteinligand and protein-protein interactions. Meanwhile, challenges, noted by low accuracy and combinatoric issues, may also cause failures. In this review, state-of-the-art techniques for protein modeling (e.g. structure prediction, modeling protein flexibility, etc.), hit identification/ optimization (e.g. molecular docking, focused library design, fragment-based design, molecular dynamic, etc.), and polypharmacology design will be discussed. We will explore how structure-based techniques can facilitate the drug discovery process and interplay with other experimental approaches.
Export Options
About this article
Cite this article as:
Chen Lu, K. Morrow John, T. Tran Hoang, S. Phatak Sharangdhar, Du-Cuny Lei and Zhang Shuxing, From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets, Current Pharmaceutical Design 2012; 18 (9) . https://dx.doi.org/10.2174/138161212799436386
DOI https://dx.doi.org/10.2174/138161212799436386 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volum 2
Current Diabetes Reviews Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipids in the Diet and the Fatty Acid Profile in Beef: A Review and Recent Patents on the Topic
Recent Patents on Food, Nutrition & Agriculture Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Novel Molecules Targeting Dyslipidemia and Atherosclerosis
Current Medicinal Chemistry Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Current Drug Safety Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism
Current Pharmaceutical Design Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Streptococcal Collagen-like Protein 1 Binds Wound Fibronectin: Implications in Pathogen Targeting
Current Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery